MedTrace Logo

A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

NCT04630353 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-09-12

No results posted yet for this study

Summary

This Window of Opportunity clinical trial will examine the immunologic effects of the study agent HB-201 in the head and neck or cervical cancer, when administered by IV route.

Conditions

  • HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer

Interventions

DRUG

HB-201 IV

HB-201 given IV, one (1) time, on day 1.

DRUG

HB-201 IV

HB-201 given IV, one (1) time, 7 to 14 days prior to definitive chemoradiation.

Sponsors & Collaborators

  • Hookipa Biotech GmbH

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · Hookipa Biotech GmbH

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-28
Primary Completion
2023-11-28
Completion
2023-11-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04630353 on ClinicalTrials.gov